| Test name | Alternative name for |
|---|
| 11 Deoxy-Cortisol | |
| 16S rRNA Bacterial Identification | |
| 17-Hydroxyprogesterone | |
| 1p/19q gene deletion in Oligodendrogliomas - Paraffin FISH | |
| 2019-nCoV PCR | COVID-19 PCR |
| 25-Hydroxyvitamin D | |
| 2TMSS | Maternal Serum Screening (MSS) |
| 5 Flucytosine | |
| 5-HIAA and metabolites (as part of Phenylalanine Challenge Test) | CSFHVAHIAA |
| 5-HT | Serotonin |
| 5-Hydroxytrptamine | Serotonin |
| 5FC | 5 Flucytosine |
| 5HIAA; Urine | |
| 6-MMP | Thiopurine Metabolites |
| 6-TGN | Thiopurine Metabolites |
| 9-OH risperidone | Risperidone |
| A1AT | alpha-1 Antitrypsin |
| Active-B12 | Holotranscobalamin |
| ADAMTS-13 Activity | |
| AH50 | Total Haemolytic Complement |
| AHUS1 | Complement Factor H |
| Allergen to Omega-5 Gliadin | |
| alpha-1 Antitrypsin | |
| alpha-1 Antitrypsin Genotyping | |
| alpha-1 Antitrypsin Phenotyping | |
| alpha-1 Antitrypsin; Faeces | |
| Alpha-amino-3-hydroxy-5-methyl-4-isoxazol-propionic-acid receptors 1 & 2 | AMPA receptor Ab |
| Aluminium Urine (24hr) | |
| AMA M2 | Anti-Liver Antibody Panel |
| AMA M2-3E | Anti-Liver Antibody Panel |
| AMBP1 | Complement Factor H |
| AML1-ETO | RUNX1-RUNX1T1 Gene Fusion |
| Androstenedione; delta-4 | delta-4 Androstenedione |
| angiotensin II type 1 receptor (AT1R) antibodies | HLA Antibodies |
| Anti CV2 antibodies | Anti-Neuronal antibodies |
| Anti GQ1b Antibodies | |
| Anti Ma1 antibodies | Anti-Neuronal antibodies |
| Anti Ma2 antibodies | Anti-Neuronal antibodies |
| Anti Mi-2 | Extended ENA Autoantibody Panel Sendaway |
| Anti Mi-2 | Anti Myositis antibodies |
| Anti Monosialoganglioside-GM1 | |
| Anti PNMA2(Ma2/Ta) antibodies | Anti-Neuronal antibodies |
| Anti SOX1 antibodies | Anti-Neuronal antibodies |
| Anti Xa for Clexane Therapy | |
| Anti Xa for Fragmin Therapy | |
| Anti Xa for Fraxiparine Therapy | |
| Anti Xa for Heparin Therapy | |
| Anti Xa for Orgaran Therapy | |
| Anti- PL-12 | Anti Myositis antibodies |
| Anti-Aquaporin 4 Ab | Anti-NMO IgG Antibody |
| Anti-Aquaporin 4 Ab CSF | Anti-NMO IgG Antibody |
| Anti-DFS-70 | Extended ENA Autoantibody Panel Sendaway |
| anti-glycoprotein-210 Ab | Anti-Liver Antibody Panel |
| Anti-IgLON5 antibodies | |
| Anti-Jo-1 | Anti Myositis antibodies |
| anti-liver cystolic antigen type 1 Ab | Anti-Liver Antibody Panel |
| anti-Mitochondrial M2 Ab | Anti-Liver Antibody Panel |
| Anti-PL7 | Anti Myositis antibodies |
| Anti-Pm/Scl(75&100) | Anti Myositis antibodies |
| Antiphospholipid Antibodies ***WESTERN HEALTH ONLY CARESET | |
| Antithrombin III | |
| Apo A1 | Apolipoproteins |
| AQP4 | Anti-NMO IgG Antibody |
| AQP4 CSF | Anti-NMO IgG Antibody |
| ARMD4 | Complement Factor H |
| ARMS1 | Complement Factor H |
| Arsenic Urine (24hr) | |
| B12 | Vitamin B12 |
| B2GP1 | beta-2 Glycoprotein 1 Antibodies IgG |
| BCL1-IgH Fusion Gene Analysis | |
| BCL2 Translocation | |
| BCR::ABL resistance mutation | |
| BCR::ABL T315I Mutation at IMVS | BCR::ABL resistance mutation |
| beta-2 Glycoprotein 1 Antibodies IgG | |
| beta-2 Microglobulin | |
| Beta-2 transferrin | Asialotransferrin; Fluid |
| BP 180_230 antibodies | |
| BP180 | Dermatology Profile ELISA |
| BP230 | Dermatology Profile ELISA |
| Breast Cancer Gene 1 | |
| Breast Cancer Gene 2 | |
| Bullous Pemphigoid 180_230 antibodies | BP 180_230 antibodies |
| C1 Esterase Inhibitor | |
| C1EI | C1 Esterase Inhibitor |
| C2 Complement | |
| C282Y | Hereditary Haemochromatosis Gene |
| C3 Complement | |
| C4 Complement | |
| C5NIA | NT5C1A |
| C6 Complement | |
| C7 Complement | |
| C8 Complement | |
| C9 Complement | |
| C9ORF72 Gene | |
| CA 15-3 | |
| CA 19-9 | |
| CA-125 | |
| Cadherin-1 Gene | |
| Cadmium Urine (24hr) | |
| CBFB-MYH11 fusion transcript | |
| CCR5-CXCR4 Tropism | |
| CD2/CD3 T Cell Markers | |
| CD34 Count | |
| CD4/CD8 T Cell Markers | |
| CFHL3 | Complement Factor H |
| CH100 | Total Haemolytic Complement |
| CH50 | Total Haemolytic Complement |
| Chromium Urine (24hr) | |
| CN1 Antibody | NT5C1A |
| Co-Enzyme Q10 | |
| Cobalt Urine (24hr) | |
| Complement C1q | |
| Connexin 26 | |
| Copper Urine (24 hr) | |
| COVID-19 PCR | |
| CV2 antibodies | Anti-Neuronal antibodies |
| CYP2C19 | Pharmacogenomic testing
This test is currently being reviewed For information regarding this test please contact the senior scientist on duty in: Human Molecular |
| CYP2C9 | Pharmacogenomic testing
This test is currently being reviewed For information regarding this test please contact the senior scientist on duty in: Human Molecular |
| CYP2D6 | Pharmacogenomic testing
This test is currently being reviewed For information regarding this test please contact the senior scientist on duty in: Human Molecular |
| Cytochrome P450 | Pharmacogenomic testing
This test is currently being reviewed For information regarding this test please contact the senior scientist on duty in: Human Molecular |
| Cytosolic 5' Nucleotidase | NT5C1A |
| Cytosolic 5-nucleotidase 1A | NT5C1A |
| delta-4 Androstenedione | |
| Desmoglein 1,3 antibodies | |
| DFS70 | Extended ENA Autoantibody Panel Sendaway |
| Dipeptidyl-peptidase-like protein 6 | Anti-DPPX antibodies (serum) |
| DM2 Exclusion | Myotonic Dystrophy Type 2 Exclusion |
| DOCK 8 expression | |
| DOCK8 | DOCK 8 expression |
| DSG1 and 3 | Desmoglein 1,3 antibodies |
| Dystonia DYT1-GAG deletion | DYT1 Gene |
| DYT1 Gene | |
| E3 | Oestriol |
| E5M | Eosin-5-Maleimide |
| ELA2 Mutation | Myeloid NGS |
| EMI BEAS8 | Emicizumab Factor VIII Inhibition Level |
| EMI F8L | Emicizumab Factor VIII Level |
| Emicizumab Factor 8 Bethesda Level | Emicizumab Factor VIII Inhibition Level |
| Emicizumab Factor 8 level | Emicizumab Factor VIII Level |
| Emicizumab Factor VIII Inhibition Level | |
| Emicizumab Factor VIII Level | |
| EOSIN 5 MALEIMIDE FOR HS | Eosin-5-Maleimide |
| Eosin-5-Maleimide | |
| F10L | Factor X |
| F11L | Factor XI |
| F12L | Factor XII |
| F13 | Factor XIII Assay, |
| F13L | Factor XIII Assay, |
| f20 | Allergen to Almond |
| f211 | Allergen to Blackberry |
| f237 | Allergen to Apricot |
| f27 | Allergen to Beef |
| F2L | Factor II |
| f313 | Allergen to Anchovy |
| f319 | Allergen to Beetroot |
| f45 | Allergen to Bakers Yeast |
| f49 | Allergen to Apple |
| F5L | Factor V Leiden Mutation |
| F5L | Factor V |
| f6 | Allergen to Barley |
| F7 | Factor VII |
| F7L | Factor VII |
| F8L | Factor VIII |
| f92 | Allergen to Banana |
| f96 | Allergen to Avocado |
| F9L | Factor IX |
| Factor 10 | Factor X |
| Factor 10 assay | Factor X |
| Factor 11 | Factor XI |
| Factor 12 | Factor XII |
| Factor 13 Assay | Factor XIII Assay, |
| Factor 2 | Factor II |
| Factor 5 | Factor V |
| Factor 7 | Factor VII |
| Factor 8 | Factor VIII |
| Factor 9 | Factor IX |
| Factor II | |
| Factor II Inhibition Level | |
| Factor IX | |
| Factor IX Gene Mutation | |
| Factor IX Inhibition Level | |
| Factor V | |
| Factor V Inhibition Level | |
| Factor VII | |
| Factor VII Inhibition Level | |
| Factor VIII | |
| Factor VIII Binding Assay | |
| Factor VIII Gene Mutation | |
| Factor VIII Inhibition Level | |
| Factor X | |
| Factor X Inhibition Level | |
| Factor XI | |
| Factor XI Inhibition Level | |
| Factor XII | |
| Factor XII Inhibition Level | |
| Factor XIII Assay, | |
| Factor XIII Inhibition Level | |
| Faecal alpha-1 Antitrypsin | alpha-1 Antitrypsin; Faeces |
| FGF23 | |
| FHL1 | Complement Factor H |
| Fibroblast Growth Factor 23 | FGF23 |
| FIP1L1-PDGFRA | |
| FK506 | Tacrolimus |
| FLT3-ITD | FLT3/NPM1 mutation screening |
| FLT3-ITD MRD | |
| FLT3-ITD NGS | FLT3-ITD MRD |
| FLT3-TKD | FLT3/NPM1 mutation screening |
| FLT3/NPM1 mutation screening | |
| FMR1 | Fragile X DNA Analysis |
| FMR1 Triplet Repeat | Fragile X DNA Analysis |
| Free T3 | |
| Free T4 | |
| FTDP-17 | MAPT Gene Test |
| G20210A | Prothrombin G20210A Mutation |
| G6PD Quantitation | |
| G6PD Screen | |
| Gamma- amino-butryic acid b1/B2 receptors antibodies | GABA(B) autoantibodies |
| Ganglionic Antibody (alpha-3 acetylcholine receptor) | |
| Glucose-6-Phosphate Dehydrogenase Quantitation | G6PD Quantitation |
| Glucose-6-Phosphate Dehydrogenase Screen | G6PD Screen |
| GluR1/GluR2 | AMPA receptor Ab |
| Glycoprotein 1 Antibodies; Beta-2 | beta-2 Glycoprotein 1 Antibodies IgG |
| GM1 ab. | Anti Monosialoganglioside-GM1 |
| Gngl Ab (a3 ACHR) | Ganglionic Antibody (alpha-3 acetylcholine receptor) |
| gp210 | Anti-Liver Antibody Panel |
| GQ1b Antibodies | Anti GQ1b Antibodies |
| H630 | Hereditary Haemochromatosis Gene |
| HA1C | Haemoglobin A1c |
| Haemoglobin A1c | |
| HBA1C | Haemoglobin A1c |
| HbA2 | Haemoglobin Electrophoresis |
| HCO3 | Bicarbonate |
| Heparin Cofactor II | |
| HER2 ISH Paraffin Section | |
| HF1 | Complement Factor H |
| HF2 | Complement Factor H |
| HH6V Serology | Human Herpes 6 Virus Serology |
| HH8V PCR | Human Herpes 8 Virus PCR |
| HHV6 PCR | Human Herpes 6 Virus PCR |
| HHV6 Serology | Human Herpes 6 Virus Serology |
| HHV8 PCR | Human Herpes 8 Virus PCR |
| Histology - HER2 ISH – Paraffin Section | HER2 ISH Paraffin Section |
| HIV p24 Antigen | P24 HIV Antigen Serology |
| HIV Serology (Confirmation) | |
| HIV-1 Integrase Inhibitor Susceptibility | |
| HIV-1 PCR | |
| HIV-1 PCR on Seminal Plasma | |
| HIV-2 PCR | |
| HLA B27 | |
| HLA B51 | |
| HLA B57 | |
| HSV 1 & 2 PCR – Formalin Fixed Paraffin Sections | |
| HSV-1 PCR | Herpes Virus Multiplex PCR |
| HSV-2 PCR | Herpes Virus Multiplex PCR |
| HTLV 1 PCR | |
| HTLV 1/2 Antibodies | |
| Human Herpes 6 Virus PCR | |
| Human Herpes 6 Virus Serology | |
| Human Herpes 8 Virus PCR | |
| Hydroxyindoleacetic Acid 5; Urine | 5HIAA; Urine |
| IA2 Antibodies | |
| IBM (NT5C1A) Antibody
Anti-cN1A | NT5C1A |
| IDH1/IDH2 mutation MRD | |
| IDH1/IDH2 dPCR | IDH1/IDH2 mutation MRD |
| IGF1 | Insulin Like Growth Factor 1 |
| IGFBP-3 | |
| IgLON5CSF | Anti-IgLON5 antibodies |
| IL-6 | |
| IL28B Genotype | |
| IL6 | IL-6 |
| Inhibition Level Factor 10 | |
| Inhibition Level Factor 11 | |
| Inhibition Level Factor 2 | |
| Inhibition Level Factor 5 | |
| Inhibition Level Factor 7 | |
| Inhibition Level Factor 8 Porcine | |
| Inhibition Level Factor 9 | |
| Insulin Like Growth Factor 1 | |
| Insulin-like Growth Factor Binding Protein-3 | IGFBP-3 |
| Interleukin-6 | IL-6 |
| inv(16) | CBFB-MYH11 fusion transcript |
| inv16 | CBFB-MYH11 fusion transcript |
| Iodine Urine (24hr) | |
| Iron Urine (24hr) | |
| JAK2 exon 12 | Myeloid NGS |
| JAK2 mutation | JAK2 V617F |
| JAK2 V617F | |
| Jo-1 | ENA |
| Jo-1 | Anti Myositis antibodies |
| KIT D816V | |
| KMT2A Measureable residual disease | KMT2A-X MRD |
| KMT2A-X MRD | |
| LC-1 | Anti-Liver Antibody Panel |
| LC1 | Anti-Liver Antibody Panel |
| Lead Urine (24hr) | |
| Legionella pneumophila serogroup 1 antigen | |
| LKM-1 | Anti-Liver Antibody Panel |
| Lyso-GB1 | Glucosylsphingosine |
| Ma1 antibodies | Anti-Neuronal antibodies |
| Ma2 antibodies | Anti-Neuronal antibodies |
| Manganese Urine (24hr) | |
| MDA5 | Anti Myositis antibodies |
| MELAS 3243 Mutation | |
| Mercury Urine (24 hr) | |
| Mi-2 antibodies | Anti Myositis antibodies |
| Mi-2 antibody | Extended ENA Autoantibody Panel Sendaway |
| Microglobulin; beta 2 | beta-2 Microglobulin |
| Motor Neurone Disease Gene | |
| MS DM1 | Myotonic Dystrophy Gene type 1 |
| MS NOTCH3 | NOTCH3 Mutation Testing |
| MT-ND1 m.3460G>A | LHON Mutation Analysis |
| MT-ND4 m.11778G>A | LHON Mutation Analysis |
| MT-ND6 m.14484T>C | LHON Mutation Analysis |
| Mup44 | NT5C1A |
| Muscle protein 44 | NT5C1A |
| MYD88 ddPCR | MYD88 L265P mutation |
| MYD88 L265P mutation | |
| Myotonic Dystrophy Gene type 1 | |
| Myotonic Dystrophy Type 2 Exclusion | |
| NfL
Phospho-Tau181P; Neurofilament Light | Alzheimer's Disease (Blood) |
| NH3 | Ammonia |
| Nickel Urine (24hr) | |
| Nor90 | Scleroderma Antibody Line Immunoassay |
| NOTCH3 Mutation Testing | |
| Novel Coronavirus 2019 PCR | COVID-19 PCR |
| NPM1 mutant MRD | |
| NS1 Antigen | Dengue Virus Serology |
| NT5C1a | NT5C1A |
| NT5C1A | |
| NT5C1A Antibody | NT5C1A |
| Nucleic Acid Testing (HIV-1, HCV, HBV) | |
| NUDT15 | TPMT Genotype |
| NXP2 | Anti Myositis antibodies |
| ODG 1p/19q LOH - Paraffin FISH | 1p/19q gene deletion in Oligodendrogliomas - Paraffin FISH |
| Omega 3 | Essential Fatty Acids |
| p190 | BCR::ABL Transcript |
| P1NP | |
| p210 | BCR::ABL Transcript |
| P24 HIV Antigen Serology | |
| P3NP | PIIINP |
| PCA-1 antibodies | Anti-Neuronal antibodies |
| PF 1+2 | Prothrombin Fragments 1&2 |
| PF1+2 | Prothrombin Fragments 1&2 |
| PFA-100 | Platelet Aggregation Studies |
| PFA-200 | Platelet Aggregation Studies |
| PFA100 | Platelet Aggregation Studies |
| PFA200 | Platelet Aggregation Studies |
| Phospholipase 2 Receptor Antibody | |
| PHOSPHOLIPASE A2 RECEPTOR ANTIBODY | Phospholipase 2 Receptor Antibody |
| PIIINP | |
| PL-12 | Anti Myositis antibodies |
| PL7 | Anti Myositis antibodies |
| PLA2R ANTIBODY | Phospholipase 2 Receptor Antibody |
| PMP22 deletion (MLPA) | |
| PMP22 loss | PMP22 deletion (MLPA) |
| PNMA2 antibodies | Anti-Neuronal antibodies |
| PO4 | Phosphate |
| PR3 antibody | Proteinase 3 IgG |
| Procollagen type 1 amino-terminal peptide | P1NP |
| Progesterone; 17 alpha-hydroxy | 17-Hydroxyprogesterone |
| Protein 14-3-3 | Creutzfeldt-Jacob Disease Protein |
| Proteinase 3 IgG | |
| Prothrombin Fragments 1&2 | |
| Prothrombin G20210A Mutation | |
| PTH (1-84) | Parathyroid Hormone |
| Ro-52 | Anti-Liver Antibody Panel |
| Ro52 | Anti-Liver Antibody Panel |
| RP11 | Scleroderma Antibody Line Immunoassay |
| RP155 | Scleroderma Antibody Line Immunoassay |
| RUNX1-RUNX1T1 Gene Fusion | |
| SAE1 | Anti Myositis antibodies |
| SARS CoV-2 PCR | COVID-19 PCR |
| SARS-CoV-2 IgG | COVID Serology |
| SARS-CoV-2 Serology | COVID Serology |
| SCL-70 | ENA |
| Selenium Urine (24hr) | |
| sFlt-1 | Pre-eclampsia markers |
| SLCO1B1 | Pharmacogenomic testing
This test is currently being reviewed For information regarding this test please contact the senior scientist on duty in: Human Molecular |
| SOD1 gene mutation | Motor Neurone Disease Gene |
| Soluble CD25 | |
| Soluble IL-2 Receptor | Soluble CD25 |
| SOX1 antibodies | Anti-Neuronal antibodies |
| sp100 | Anti-Liver Antibody Panel |
| t(11;14) | BCL1-IgH Fusion Gene Analysis |
| t(14;18) | BCL2 Translocation |
| t(8;21) | RUNX1-RUNX1T1 Gene Fusion |
| t(9;22) | BCR::ABL Transcript |
| T3; Free | Free T3 |
| T4; Free | Free T4 |
| TH17 | |
| Th17 Cells | TH17 |
| Thallium Urine (24hr) | |
| TIF1-gamma | Anti Myositis antibodies |
| TP53 Mutation | |
| TRIM21 (Ro52) | Scleroderma Antibody Line Immunoassay |
| TRIM21(R0-52) antibodies. | Anti Myositis antibodies |
| Tumour Protein 53 Mutation | TP53 Mutation |
| Urine Arsenic Excretion(24hr) | Arsenic Urine (24hr) |
| Urine Cadmium Excretion (24hr) | Cadmium Urine (24hr) |
| Urine HCO3 | Urine Bicarbonate |
| Urine Iodine Excretion (24hr) | Iodine Urine (24hr) |
| Urine Iron Excretion (24hr) | Iron Urine (24hr) |
| Urine Lead Excretion (24hr) | Lead Urine (24hr) |
| Urine Manganese Excretion (24 hr) | Manganese Urine (24hr) |
| Urine Mercury Excretion (24 hr) | Mercury Urine (24 hr) |
| Urine Nickel Excretion (24 hr) | Nickel Urine (24hr) |
| Urine Selenium Excretion (24hr) | Selenium Urine (24hr) |
| Urine Thallium Excretion (24hr) | Thallium Urine (24hr) |
| Urine Vanadium Excretion (24hr) | Vanadium Urine (24hr) |
| Urine Zinc Excretion (24hr) | Zinc Urine (24hr) |
| Vanadium Urine (24hr) | |
| vCD3 T-cell enumeration (CTU) | vCD3CTU |
| vCD3CTU | |
| Viable CD3 enumeration (CTU) | vCD3CTU |
| Vitamin B2 | |
| Vitamin B1 | |
| Vitamin B12 | |
| Vitamin B3 (24 hr urine) | |
| Vitamin B6 | |
| Vitamin D -25(OH) | 25-Hydroxyvitamin D |
| Vitamin D3 | 25-Hydroxyvitamin D |
| Vitamin D3; 1,25 Dihydroxy | |
| Von Willebrand Disease 2N (Subtype Normandy) | Normandy (Von Willebrand Factor) Gene Analysis |
| VWD Type 2N | Normandy (Von Willebrand Factor) Gene Analysis |
| Zinc Transporter 8 Antibodies | ZnT8 Antibodies |
| Zinc Urine (24hr) | |
| ZnT8 Antibodies | |